Acurx Ended Q2 With $10.7 Million in Cash as Trial Spending Increased Acurx reported a $2.3 million quarterly loss, higher research spending and a larger cash...
https://www.narrowit.com/news/acurx-q2-cash-trial-financing-dilution-2026-08-16
#AcurxPharmaceuticals #ACXP #Ibezapolstat #CDifficile
https://www.narrowit.com/news/acurx-q2-cash-trial-financing-dilution-2026-08-16
#AcurxPharmaceuticals #ACXP #Ibezapolstat #CDifficile
Acurx Q2 Cash Rose as Trial Spending Increased | Narrowit.com
Acurx reported $10.7 million in cash, a $2.3 million Q2 loss and higher R&D spending as ibezapolstat development advanced.
www.narrowit.com
August 16, 2026 at 4:12 PM
Acurx Ended Q2 With $10.7 Million in Cash as Trial Spending Increased Acurx reported a $2.3 million quarterly loss, higher research spending and a larger cash...
https://www.narrowit.com/news/acurx-q2-cash-trial-financing-dilution-2026-08-16
#AcurxPharmaceuticals #ACXP #Ibezapolstat #CDifficile
https://www.narrowit.com/news/acurx-q2-cash-trial-financing-dilution-2026-08-16
#AcurxPharmaceuticals #ACXP #Ibezapolstat #CDifficile